







































































21.5, 16, 14 kbのDNA断片が検出されるか、近位




















1* 人口動態調査 2002 総務省，
2* 血液凝固異常全国調査，平成14年（2002）度報告書, エ
イズ予防財団
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ABSTRACT
[Object] The incidence of inhibitor development in the Tohoku region has been reported 1% 
or so, in contrast to about 3% in the whole population of hemophilia patients in Japan. 
[Methods and results] We organized Tohoku hemophilia inhibitor working group (Tohoku 
HIWG) and investigated the incidence of inhibitor development as wel as inversion at intron 
22 of the factor VIII/8 gene by a questionnaire survey and analysis of patients’ DNA 
samples. The clinical features of 81 reported cases (20.4% of al patients in this region) 
concerning bleeding symptoms were the same as reported previously by other Japanese 
investigators. Factor VIII/8 or IX/9 concentrate has been used for prophylactic replacement 
therapy in about 50% of patients regardless of the severity of their disease states. The 
incidence of inhibitor development was 9.9% in our patients with hemophilia; 11.9% in patients 
with hemophilia A and 19.5% in patients with severe hemophilia A. Inversion at intron 22 of 
the factor VIII/8 gene was found in 29% of patients with hemophilia A examined here, and 
one among two patients with inhibitor.
[Conclusion] These results are the same as the nation-wide surveilance of the al hemphilic 
patients in whole Japan.
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